NCT03063437已完成2 期
Phase II Randomized, Double Blind, Placebo-controlled, Parallel Group Trial of Encapsulated Fecal Microbiota Transplantation for Vancomycin Resistant Enterococcus Decolonization
Microbiome Health Research Institute4 个研究点 分布在 1 个国家目标入组 9 人开始时间: 2017年8月17日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 9
- 试验地点
- 4
- 主要终点
- Percentage of Participants With VRE Decolonization
研究概览
简要总结
The objective of this study is to provide preliminary insight into the safety and efficacy of fecal microbiota transplantation (FMT) for the eradication of gastrointestinal carriage of vancomycin-resistant Enterococcus.
详细描述
Note: The Protocol and Statistical Analysis Plan document contains modifications from what is on file at the FDA to reflect redactions and formatting requirements for public posting on ClinicalTrials.gov.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Adults 18 years or older at the time of enrollment.
- •Able to provide signed and dated informed consent.
- •Identified as VRE-positive by a stool culture within last 14 days.
- •Women of childbearing potential in sexual relationships with men must use an acceptable method of contraception§ from 30 days prior to enrollment until 4 weeks after completing study treatment.
- •Males must agree to avoid impregnation of women during and for four weeks after completing study treatment through use of an acceptable method of contraception*.
- •Includes, but is not limited to, barrier with additional spermicidal foam or jelly, intrauterine device, hormonal contraception (started at least 30 days prior to study enrollment), intercourse with men who underwent vasectomy.
- •Includes, but is not limited to, barrier with additional spermicidal foam or jelly and vasectomy.
排除标准
- •Female patient who are pregnant, lactating or planning on becoming pregnant during study. Female patients of childbearing potential will undergo a pregnancy test, and be excluded from the study if positive.
- •Inability (e.g. dysphagia) to or unwilling to swallow capsules.
- •Active antibiotic resistant bacteria (ARB) or gastrointestinal infection at time of enrollment.
- •Patient received antibiotics in the last 48 hours. Patients will be eligible to enroll if antibiotic therapy is discontinued for at minimum 48 hours prior to randomization. Does not include antibiotics used for prophylaxis or topical antibiotics.
- •Requires continued antibiotic use or anticipates antibiotic use in the upcoming 4 weeks. Does not include antibiotics used for prophylaxis or topical antibiotics.
- •Unwilling to withhold probiotics for a minimum of 48 hours prior to providing a screening stool sample.
- •Known or suspected toxic megacolon and/or known small bowel ileus.
- •Major gastrointestinal surgery (e.g. significant bowel resection) within 3 months before enrollment. This does not include appendectomy or cholecystectomy.
- •History of total colectomy or bariatric surgery.
- •Admitted to or expected to an intensive care unit for medical reasons (not just boarding). Patients residing in a nursing home, long-term care facility or rehabilitation center may be enrolled.
- •Concurrent intensive induction chemotherapy, radiation therapy or biological treatment for active malignancy. Patients on maintenance chemotherapy may be enrolled only after consultation with medical monitor.
- •Unable or unwilling to comply with protocol requirements.
- •Expected life expectancy < 6 months
- •Previous FMT or microbiome-based products at any time excluding this study.
- •Patients with a history of severe anaphylactic or anaphylactoid food allergy.
- •Solid organ transplant recipients ≤ 90 days post-transplant or on active treatment for rejection.
- •Neutropenia (≤500 neutrophils/mL) or other severe immunosuppression. Anti-TNF will be permitted. Patients on monoclonal antibodies to B and T cells. glucocorticoids, antimetabolites (azathioprine, 6-mercaptopurine, methotrexate), calcineurin inhibitors (tacrolimus, cyclosporine) and mycophenolate mofetil may be enrolled only after consultation with the medical monitor.
- •If at risk for CMV/EBV associated disease (at investigator's discretion, e.g. immunocompromised), negative IgG testing for cytomegalovirus (CMV) or Epstein Barr Virus (EBV).
- •A condition that would jeopardize the safety or rights of the subject, would make it unlikely for the subject to complete the study, or would confound the results of the study.
结局指标
主要结局
Percentage of Participants With VRE Decolonization
时间窗: Day 10 (±3 days) after randomization
VRE decolonization is defined by absence of VRE on stool culture using standard clinical laboratory techniques at Day 10 (± 3 days) after randomization.
Percentage of Participants With an Adverse Event (AE); Severe Adverse Event (SAE); and Newly Acquired Transmissible Infectious Diseases Which Are Considered Adverse Events of Special Interest (AESI)
时间窗: Day 10 (±3 days) after randomization
Percentage of participants with an adverse event (AE); severe adverse event (SAE); and newly acquired transmissible infectious diseases which are considered adverse events of special interest (AESI) through Day 10 (± 3 days) after randomization.
次要结局
- Number of Days Between FMT and VRE Colonization and Infection Occurs(Up to 6 months after randomization)
- VRE Decolonization Among Immunocompromised Patients(Day 10 (± 3 days) after randomization)
- Percentage of Participants With VRE Infection(Week 4 (±5 days) after randomization)
- Percentage of Participants With ARB Colonization on Day 10 Following Fecal Microbiota Transplantation (FMT)(Day 10 (± 3 days) after randomization)
- Percentage of Participants With ARB Infection 4 Weeks Following FMT(Week 4 (±5 days) after randomization)
- Serious Adverse Events Within 4 Weeks Following FMT(Week 4 (±5 days) after randomization)
- Newly Acquired Transmissible Infectious Diseases Which Are Considered Adverse Events of Special Interest (AESI)(Week 4 (±5 days) after randomization)
- Adverse Events Within 4 Weeks Following FMT(Week 4 (±5 days) after randomization)
- Serious Adverse Events Within 6 Months Following FMT(Month 6 (±14 days) phone safety assessment after randomization)
研究者
研究点 (4)
Loading locations...
相似试验
终止
2 期
Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis SuppurativaHidradenitis SuppurativaNCT01838499AstraZeneca224
Unknown
不适用
Clinical Study on the Fecal Microbiota Transplantation in the Treatment of Ulcerative Colitis With DepressionUlcerative ColitisNCT05030064Third Military Medical University54
终止
2 期
Randomized, Controlled Trial of Extended-Release Niacin (Niaspan®) to Augment Subacute Ischemic Stroke RecoveryIschemic StrokeNCT00796887Henry Ford Health System27
已完成
2 期
Safety, Pharmacokinetics and Efficacy Study of CVT-301 Inpatients With Parkinson's Disease and "Off" EpisodesIdiopathic Parkinson's DiseaseNCT01617135Acorda Therapeutics25
撤回
2 期
Pharmacokinetics and Pharmacodynamics of MTR105 in Hypotensive Cardiac Surgery PatientsCardiopulmonary BypassHypotensionNCT00482287Meditor Pharmaceuticals Ltd.